Search

Displaying results 2461 - 2470 of 2489 in total
  1. Drug

    P-42 peptide

    go.drugbank.com/drugs/DB18610
    Experimental

    P-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein

  2. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    Taletrectinib is an orally available small molecule kinase inhibitor. It is targeted against ROS1, including resistant mutant forms, and shows some inhibitor activity against tropomyosin receptor kinases (TRKs) TRKA, TRKB, and TRKC. Gene...

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  3. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-produc...

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  4. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. By b...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Enavogliflozin

    go.drugbank.com/drugs/DB18970
    Investigational

    Enavogliflozin is under investigation in clinical trial NCT06399835 (Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    Vepdegestrant is a potent, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) small molecule estrogen receptor (ER) degrader. It was identified through a targeted medicinal chemistry optimization campaign to act as...

    Categories: Cytochrome P-450 CYP2B6 Inhibitors, P-glycoprotein inhibitors
  8. Drug

    Aminoflavone

    go.drugbank.com/drugs/DB19077
    Investigational

    Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  9. Drug

    Arketamine

    go.drugbank.com/drugs/DB19150
    Investigational

    Arketamine is under investigation in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and Efficacy of PCN-101 in TRD).

    Categories: Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 Substrates
  10. Drug

    Substance P

    go.drugbank.com/drugs/DB19198
    Investigational

    Substance P is under investigation in clinical trial NCT03738878 (Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1).

    Categories: Substance P, antagonists & inhibitorsSynonyms: Neurokinin p, Substance P